Quarterly ResultAug 10, 2026, 04:41 PM
Perspective Therapeutics Q2 Net Loss $26.8M; Raises $175M in Offering
AI Summary
Perspective Therapeutics reported a net loss of $26.8 million for the second quarter of 2026 and $53.0 million for the first six months of 2026. The company significantly strengthened its financial position by raising approximately $175.0 million in gross proceeds from a registered offering of common stock and pre-funded warrants in February 2026. As of June 30, 2026, cash, cash equivalents, and short-term investments totaled $236.9 million, which is expected to fund current planned operations into late 2027. The company also detailed ongoing investments in manufacturing infrastructure, including facility modifications and equipment purchases for its radiopharmaceutical product candidates.
Key Highlights
- Raised $175.0 million gross proceeds from a registered offering of common stock and pre-funded warrants in February 2026.
- Reported a net loss of $26.8 million for the three months ended June 30, 2026, compared to $21.5 million in Q2 2025.
- Six-month net loss for 2026 was $53.0 million, up from $39.7 million in the prior year period.
- Cash, cash equivalents, and short-term investments totaled $236.9 million as of June 30, 2026.
- Research and development expenses increased to $42.9 million for the six months ended June 30, 2026.
- Property and equipment, net, grew to $107.8 million from $76.6 million at December 31, 2025.
- Entered agreements for $53.3 million in building modifications for manufacturing facilities.
- Recognized $1.4 million in other income from a related party from the Option Agreement.
Price Impact
More from CATX